Spotlight Innovation — Investor Presentation (June 2017)
23 slides from Spotlight Innovation's investor presentation, Jun 16, 2017
Slide 1: Spotlight Innovation
POTLIGHT ) INNOVATION Add essing unmet medical needs jn rare, emerging and, neglected diseases }
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Statements in this document that are not purely historical are forward-looking statements. Forward- looking statements in this document include statements regarding the Company's efforts to develop and commercialize its various technologies. Actual outcomes and actual results c
Slide 3: Therapeutic Focus
THERAPEUTIC FOCUS Accelerated Path To Market Rapid Clinical Trial Recruitment Support from Patient Advocates Extended Market Exclusivity SPOTLIGHT INNOVATION Page 1
Slide 4: Selected Companies Targeting Rare Diseases
SELECTED COMPANIES TARGETING RARE DISEASES Shire Alexion Pharmaceuticals BioMarin Pharmaceutical Bluebird Bio Intercept Pharmaceuticals Ultragenyx Pharmaceutical AveXis Sarepta Therapeutics SPOTLIGHT. INNOVATION SHPG ALXN BMRN BLUE ICPT RARE AVXS SRPT 1996 1999 2013 2012 2014 2016 2008 $23B $15B $3.
Slide 5: Activities
ACTIVITIES IP Licensing Intellectual property acquisition from universities and medical centers Business Development Access to industry leaders for joint ventures or M&A. Outsourcing . Collaboration with ) academic labs, CROs and CMOs R&D Expert Advice beet at anid Guidance from hands-on ~ y/o nial
Slide 6: Programs
PROGRAMS INTERNAL PROGRAMS + Crotoxin, a novel cancer treatment + Venodol, an over-the-counter (OTC) derived from rattle snake venom analgesic derived from cobra venom + Existing drugs repurposed to treat + STL-182, a novel, orally-available ZIKV infection ‘small molecule to treat SMA EXTERNAL INVES
Slide 7: Selected Products Derived From Toxins
SELECTED PRODUCTS DERIVED FROM TOXINS Captopril Bristol-Myers Squibb ACE inhibitor Pit viper venom Integrilin Merck Antiplatelet drug Rattlesnake venom Botox Allergan Antispastic drug CC. Botulinum toxin Exenatide AstraZeneca Incretin mimetic Gila monster venom Prialt Jazz Pharmaceuticals Analgesic
Slide 8: Cancer: Unmet Need
CANCER: UNMET NEED © Globally, cancer is the second leading cause of death (nearly 1 in 6 deaths) © Inthe U.S., approximately 1.7 million new cancer cases are expected to be diagnosed in 2017 © More than 15 million Americans with a history of cancer were alive on January 1, 2016 ‘Sources: WHO and Am
Slide 9: Chronic Pain: Unmet Need
CHRONIC PAIN: UNMET NEED * Chronic pain diminishes quality-of-life for tens of millions of Americans + Since 1999, the amount of prescription opioids sold in the U.S. nearly quadrupled + Deaths from prescription opioids have more than quadrupled since 1999 psn goxldrugoverdoselepideme! CHRONIC PAIN:
Slide 10: ZIKV Infection: Unmet Need
ZIKV INFECTION: UNMET NEED ® ZIKV outbreak is an international public health emergency © ZIKV can be spread by the bite g of an infected Aedes species mosquito a ® © ZIKV can be passed from a yw ype enasine Sab th Mioepay pregnant woman to her fetus so ut ny a ® ZIKV infection in women can cause neu
Slide 11: ZIKV Infection: Potential Therapy
ZIKV INFECTION: POTENTIAL THERAPY © Candidate drugs in preclinical trials at Florida State University (FSU) + Company-sponsored research directed by Prof. Hengli Tang aimed at developing safe and effective drugs to treat patients infected with ZIKV Professor Hengli Tang, Dept. of Biological Science,
Slide 12: ZIKV Infection in the U.S.
ZIKV INFECTION IN THE U.S. Laboratory-confirmed Zika virus disease cases as of December 2016 # of Cases Reported 0 1-11 12-22 23-49 @ 50-100 @ >100 SOURCE: coc ® 5,000+ symptomatic disease cases in U.S. States ® 38,000+ symptomatic disease cases in U.S. Territories SPOTLIGHT INNOVATION Page 10
Slide 13: Spinal Muscular Atrophy (SMA): Unmet Need
SPINAL MUSCULAR ATROPHY (SMA): UNMET NEED © Autosomal recessive motor neuron disease carried by 1 in 40 to 1 in 50 adults ® Leading genetic cause of death in infants and toddlers ® 1in 6,000 to 1 in 10,000 newborns are affected ® 60% of patients progressively lose muscle control and die by age two ©
Slide 14: SMA: Potential Therapies
SMA: POTENTIAL THERAPIES ana Sa Starus ‘SMN2 splicing modifier Roche Olesoxime Oral Neuroprotective agent Phase 2 Roche/PTC RG7916 Oral 'SMN2 splicing modifier Phase 2 z Skeletal muscle troponin Astellas/Cytokinetics CK-107 Oral rs Phase 2 Novartis LMLO70 Oral SMN2 splicing modifier Phase 1/2 AveXis
Slide 15: Nusinersen: Current Therapy for SMA
NUSINERSEN: CURRENT THERAPY FOR SMA Recent FDA approval and commercial launch of nusinersen may: ® Validate commercial viability of SMA © Increase public awareness of SMA © Establish protocols for insurance coverage © Justify routine newborn genetic screening * Identification of subjects for future
Slide 16: Refractory Glaucoma — Investment in Solx
REFRACTORY GLAUCOMA — INVESTMENT IN SOLX © Solx, Inc. develops innovative surgical technologies to treat refractory glaucoma © The SOLX Gold Shunt™ is a novel ~ treatment that safely reduces intraocular pressure (IOP) while eliminating the need for a bleb © Though the shunt is currently limited to i
Slide 17: Refractory Glaucoma — Solx (cont'd)
REFRACTORY GLAUCOMA — SOLX (cont'd) Innovative Product an First shunt to utilize natural outflow to suprachoroidal space Iterative design on SOLX Gold Shunt™ fo optimize function Durable Efficacy (Over 35% IOP reduction in difficult to treat patients Sustained IOP control >5 years, >10mmtg IOP reduc
Slide 18: Management Team
MANAGEMENT TEAM £ John M. Krohn Chief Executive Officer, President and Chief Operating Officer © 20+ years as financial services executive and entrepreneur © 10+ years public accounting and CFO experience © Spotlight Innovation’s largest investor SPOTLIGHT INNOVATION Bill Pim, CPA Chief Financial Of
Slide 19: Scientific Leadership
SCIENTIFIC LEADERSHIP Chitra Edwin, Ph.D. RAC Geoffrey Laff, Ph.D. SVP Regulatory / Compliance SVP Business Development + 20+ years in regulatory affairs * 20+ years in venture capital, and compliance competitive intelligence, market research, and business + Regulatory approvals in development infec
Slide 20: Board of Directors
BOARD OF DIRECTORS John M. Krohn Chairman of the Board Craig A. Lang | Director + President of The Prairie Strategy Group and of Windward lowa + Past Chairman of FBL Financial and Pres. of the lowa Farm Bureau Federation Sanjeev Agarwal, Ph.D. | Director + President of Technochem International, Inc.
Slide 21: Stock Information
STOCK INFORMATION Stock Symbol OTCQI TLT State of Incorporation: Nevada As of 6/15/17 Price: $0.39 52 Week Range: $0.11 - $1.75 Shares Outstanding: 34.5M Market Cap: $13.4M Float: 7.4M SPOTLIGHT INNOVATION Page 19
Slide 22: Recent Developments
RECENT DEVELOPMENTS May Spotlight Innovation Subsidiary Caretta Therapeutics Begins the Manufacturing 2017 Process for Venodol, a New Over-the-Counter Product to Treat Chronic Pain wait Spotlight Innovation Commences Part 2 of Phase | Cancer Trial Feesty” Spotlight Innovation Licenses Additional Ant
Slide 23: Contact
CONTACT Geoffrey Laff, Ph.D. Senior Vice President of Business Development Geoffrey.Laff@SpotlightInnovation.com Direct: 917-605-2725 Main Office: 515-274-9087 www.spotlightinnovation.com Investor Relations 888-684-1066 ir@spotlightinnovation.com SPOTLIGHT INNOVATION Page 21
Spotlight Innovation — Investor Presentation (June 2017) on 6ix